The Global HIV Vaccine Enterprise encourages HIV vaccine researches to submit abstracts online from 3 February to 23 April through the HIVR4P website. Late breaker abstracts will be accepted from 23 July – 5 August. Abstracts about HIV vaccine research and development can be submitted across a range of categories from basic science to product implementation.
The Global HIV Vaccine Enterprise (the Enterprise), hosted by the International AIDS Society (IAS), shares the deep disappointment that the Phase 2b/3 HIV vaccine study HVTN 702 has been stopped by the trial sponsor, the National Institute of Allergy and Infectious Diseases (NIAID). The decision to halt the trial, conducted by the HIV Vaccine Trials Network (HVTN), follows the recommendation of the independent Data and Safety Monitoring Board (DSMB). Although the regimen did not prevent HIV infections, the DSMB did not express any concerns about safety.
The Global HIV Vaccine Enterprise (the Enterprise) meeting in Ghent, Belgium, provided an opportunity to engage as a region on critical issues, including political and research commitments in Europe, with the aim of ensuring that HIV vaccine R&D remains a key priority in a challenging and changing global health landscape.
In this viewpoint published in The Lancet, key stakeholders look into the challenges of developing an HIV vaccine from development to marketing.
The Global HIV Vaccine Enterprise is looking forward to the 20th International Conference on AIDS and STIs in Africa (ICASA 2019) taking place on 2-7th December 2019 in Kigali, Rwanda.
ICASA represents the largest AIDS conference in Africa with over 10 000 delegates expected. The conference theme for 2019 is “AIDS free Africa – Innovation, Community and Political Leadership”. This is a tremendous opportunity for the international community to join efforts in committing to achieving an AIDS-free Africa.
The Enterprise welcomes the European Union (EU) commitment to increase health security in sub-Saharan Africa and Europe, building on the current partnership between the EU, its Member States and sub-Saharan countries. These partnerships are essential for facilitating research, developing and improving health technologies, which in turn contributes to reducing the burden of infectious diseases.
The Global HIV Vaccine Enterprise welcomes the important and encouraging results of the ASCENT study and new clinical data from the APPROACH study presented at the 10th IAS Conference on HIV Science (IAS 2019), held in Mexico City, Mexico. These two studies build on the success of previous research using mosaic-based vaccines and provide important data to inform ongoing efforts to develop an effective, implementable vaccine regimen – a central part of a comprehensive, global HIV prevention strategy.
The HIV vaccine field has built considerable momentum in recent times with multiple efficacy-stage programmes underway and new vaccine concepts in the clinical pipeline. The range of opportunities and possibilities is matched by a shared understanding and sense of urgency that the field is underprepared for the range of complex challenges that remain.
The Global HIV Vaccine Enterprise (the Enterprise) unites stakeholders to share knowledge, foster collaboration, enable solutions and expand support critical to the development of—and future access to—an HIV vaccine.
Global HIV Vaccine Enterprise
International AIDS Society
Avenue de France 23